25 research outputs found

    Characterization of the commercially-available fluorescent chloroquine-BODIPY conjugate, LynxTag-CQGREEN, as a marker for chloroquine resistance and uptake in a 96-well plate assay

    Get PDF
    Chloroquine was a cheap, extremely effective drug against Plasmodium falciparum until resistance arose. One approach to reversing resistance is the inhibition of chloroquine efflux from its site of action, the parasite digestive vacuole. Chloroquine accumulation studies have traditionally relied on radiolabelled chloroquine, which poses several challenges. There is a need for development of a safe and biologically relevant substitute. We report here a commercially-available green fluorescent chloroquine-BODIPY conjugate, LynxTag-CQGREEN, as a proxy for chloroquine accumulation. This compound localized to the digestive vacuole of the parasite as observed under confocal microscopy, and inhibited growth of chloroquine-sensitive strain 3D7 more extensively than in the resistant strains 7G8 and K1. Microplate reader measurements indicated suppression of LynxTag-CQGREEN efflux after pretreatment of parasites with known reversal agents. Microsomes carrying either sensitive or resistant-type PfCRT were assayed for uptake; resistant-type PfCRT exhibited increased accumulation of LynxTag-CQGREEN, which was suppressed by pretreatment with known chemosensitizers. Eight laboratory strains and twelve clinical isolates were sequenced for PfCRT and Pgh1 haplotypes previously reported to contribute to drug resistance, and pfmdr1 copy number and chloroquine IC50s were determined. These data were compared with LynxTag-CQGREEN uptake/fluorescence by multiple linear regression to identify genetic correlates of uptake. Uptake of the compound correlated with the logIC50 of chloroquine and, more weakly, a mutation in Pgh1, F1226Y

    Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

    Get PDF
    BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

    Accumulation of CQ<sub>GREEN</sub> and <sup>3</sup>H-CQ in PfCRT-Dd2 microsomes.

    No full text
    <p>Microsomes were incubated with 10 µM of chemosensitizers before addition of CQ<sub>GREEN</sub> or <sup>3</sup>H-CQ. Ctrl: negative control; Ver: verapamil; Mtp: methiothepin; Mgl: metergoline; Lop: loperamide; Oct: octoclothepin; Mib: mibefradil; L703: L703,606; Chl: chlorprothixene. *: p<0.05, comparing CQ<sub>GREEN</sub> uptake against control. <sup>‡</sup>: p<0.05, comparing <sup>3</sup>H-CQ uptake against control. Data presented are means ± S.E.M.; n≥3.</p

    CQ<sub>GREEN</sub> uptake by resistant-type PfCRT is inhibited by mibefradil in a dose-dependent manner.

    No full text
    <p>Microsomes were preincubated with varying concentrations of the PfCRT inhibitor mibefradil prior to addition of CQ<sub>GREEN</sub>. At the highest concentration of 10 µM, mibefradil drastically suppressed CQ<sub>GREEN</sub> uptake in PfCRT-Dd2 microsomes but had no significant effect on uptake in PfCRT-3D7 microsomes. *, ***: p<0.05 and p<0.001 respectively, against no mibefradil control (Ctrl). Data presented are means ± S.E.M.; n≥3.</p

    CQ<sub>GREEN</sub> uptake by Dd2 PfCRT microsomes.

    No full text
    <p>Total uptake of CQ<sub>GREEN</sub> was measured at various CQ<sub>GREEN</sub> concentrations in microsomes carrying Dd2 PfCRT. Non-specific uptake of CQ<sub>GREEN</sub> was measured with pre-treatment of excess unlabelled CQ. Specific uptake was estimated as the difference between total and non-specific uptake. V<sub>max</sub> and K<sub>m</sub> of the specific uptake was 938.5 nmol/mg PfCRT/min and 105.1 µM respectively. Data are means ± S.E.M.; n≥3.</p

    CQ<sub>GREEN</sub> uptake correlates with CQ resistance.

    No full text
    <p>(A) CQ<sub>GREEN</sub> fluorescence is inversely correlated with CQ logIC<sub>50</sub>. Total data set shows moderate <i>R</i><sup>2</sup> of 0.53. (B) When split into subpopulations on the basis of Pgh1 residue 1226, <i>R</i><sup>2</sup> is improved. Data shown are means of at least 3 experiments. Error bars represent S.E.M.</p

    CQ<sub>GREEN</sub> localization in <i>P. falciparum</i> 3D7.

    No full text
    <p>Parasites were stained with CQ<sub>GREEN</sub> and Hoechst and visualized via confocal microscopy under a 100× objective. CQ<sub>GREEN</sub> accumulates in the DV but also slightly stains parasite cytosol; erythrocyte cytosol is not stained. Arrowheads denote the DV. Scale bars represent 5 µm.</p

    ATP-dependent, verapamil-sensitive uptake of CQ<sub>GREEN</sub> in microsomes.

    No full text
    <p>Yeast microsomes expressing CQ-sensitive or -resistant PfCRT (“PfCRT-3D7” and “PfCRT-Dd2” respectively), or microsomes from plasmid vector control (“No PfCRT”), were incubated with CQ<sub>GREEN</sub> under different conditions. Preincubation with 150 µM verapamil abrogated CQ<sub>GREEN</sub> uptake from PfCRT-Dd2 but did not affect uptake in PfCRT-3D7 microsomes. Removal of ATP from buffer abolished CQ<sub>GREEN</sub> uptake entirely. **, ***: p<0.005 and p<0.001 respectively, against untreated control. ###: p<0.001. N.s.: not significant. Data presented are means ± S.E.M.; n≥3.</p
    corecore